PEAK6 LLC Invests $406,000 in ASP Isotopes Inc. $ASPI

Key Points

• PEAK6 LLC has acquired 86,600 shares of ASP Isotopes Inc. for approximately $406,000, representing 0.12% ownership of the company.
• Canaccord Genuity has raised its price target for ASP Isotopes from $8.50 to $11.00 and maintained a "buy" rating, indicating positive sentiment among analysts.
• ASP Isotopes reported a quarterly EPS of ($1.03), missing analysts' expectations, with revenue of $1.20 million compared to an estimate of $1.60 million.

PEAK6 LLC purchased a new stake in ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 86,600 shares of the company's stock, valued at approximately $406,000. PEAK6 LLC owned approximately 0.12% of ASP Isotopes as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in ASP Isotopes in the fourth quarter valued at approximately $34,000. SBI Securities Co. Ltd. lifted its holdings in shares of ASP Isotopes by 84.8% in the first quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after purchasing an additional 4,299 shares in the last quarter. Millennium Management LLC bought a new stake in shares of ASP Isotopes in the fourth quarter valued at about $55,000. Fortitude Advisory Group L.L.C. bought a new stake in shares of ASP Isotopes in the first quarter valued at about $64,000. Finally, ProShare Advisors LLC bought a new stake in shares of ASP Isotopes in the fourth quarter valued at about $67,000. Institutional investors own 16.80% of the company's stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group boosted their price target on ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $7.75.

Insider Activity at ASP Isotopes

In other news, Director Duncan Moore sold 75,000 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $9.28, for a total value of $696,000.00. Following the transaction, the director directly owned 994,553 shares of the company's stock, valued at $9,229,451.84. This represents a 7.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 21.40% of the company's stock.

ASP Isotopes Stock Down 0.1%

ASPI traded down $0.01 on Thursday, hitting $8.05. 4,002,779 shares of the company were exchanged, compared to its average volume of 3,210,884. ASP Isotopes Inc. has a 12 month low of $2.11 and a 12 month high of $11.68. The company has a market cap of $739.42 million, a PE ratio of -13.20 and a beta of 3.35. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. The stock's fifty day moving average is $8.98 and its 200-day moving average is $6.97.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. Equities research analysts predict that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.